Patents by Inventor Tahamtan Ahmadi

Tahamtan Ahmadi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
    Publication number: 20250066501
    Abstract: The present invention relates to methods of immunomodulation and treating patients having solid tumors with antibodies that specifically bind CD38.
    Type: Application
    Filed: September 5, 2024
    Publication date: February 27, 2025
    Inventors: Tahamtan Ahmadi, Tineke Casneuf, Henk Lokhorst, Tuna Mutis, Amy Sasser, Niels van de Donk
  • VARIANTS OF CD38 ANTIBODY AND USES THEREOF
    Publication number: 20240317881
    Abstract: Antibody variants comprising one or more mutations in the Fc region, particularly anti-CD38 antibodies comprising a mutation in one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein the amino acid residues are numbered according to the EU index.
    Type: Application
    Filed: January 23, 2024
    Publication date: September 26, 2024
    Inventors: Bart DE GOEIJ, Grietje ANDRINGA, Frank BEURSKENS, Janine SCHUURMAN, David P.E. SATIJN, Tahamtan AHMADI
  • BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA
    Publication number: 20240301078
    Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated, high-risk DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).
    Type: Application
    Filed: November 2, 2023
    Publication date: September 12, 2024
    Inventors: Brian ELLIOTT, Tahamtan AHMADI, Christopher W.L. CHIU, Esther C.W. BREIJ, Ida HIEMSTRA, Maria N. JURE-KUNKEL
  • TROGOCYTOSIS-MEDIATED THERAPY USING CD38 ANTIBODIES
    Publication number: 20240254252
    Abstract: Antibody variants for therapeutic use involving trogocytosis-mediated reduction of CD38 on CD38-expressing immunosuppressive cells; particularly CD38 antibody variants comprising one or more mutations in the Fc region, such a mutation in one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein the amino 5 acid residues are numbered according to the EU index.
    Type: Application
    Filed: July 15, 2019
    Publication date: August 1, 2024
    Inventors: Bart E. C. G. DE GOEIJ, Grietje ANDRINGA, Frank BEURSKENS, Janine SCHUURMAN, David SATIJN, Tahamtan AHMADI
  • ANTIBODY AND TAXANE COMBINATION THERAPY
    Publication number: 20240109972
    Abstract: The present invention provides combination therapy to reduce or prevent progression of a tumor or treating cancer in a subject. The combination therapy comprises administration of a binding agent that binds to human CD137 and to human PD-L1; and a taxane chemotherapeutic agent.
    Type: Application
    Filed: December 7, 2021
    Publication date: April 4, 2024
    Inventors: Ugur SAHIN, Alexander MUIK, Ulf FORSSMANN, Maria JURE-KUNKEL, Manish GUPTA, Tahamtan AHMADI, Kathy AMIRI, Gaurav BAJAJ
  • BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA
    Publication number: 20240034812
    Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated, high-risk DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).
    Type: Application
    Filed: September 10, 2021
    Publication date: February 1, 2024
    Inventors: Brian ELLIOTT, Tahamtan AHMADI, Christopher W.L. CHIU, Esther C.W. BREIJ, Ida HIEMSTRA, Maria N. JURE-KUNKEL
  • Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemia
    Patent number: 11858995
    Abstract: Provided are methods of clinical treatment of chronic lymphoblastic leukemia (CLL) in human subjects using a bispecific antibody which binds to CD3 and CD20.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: January 2, 2024
    Assignee: GENMAB A/S
    Inventors: Brian Elliott, Jenny Jianlin Chen, Tahamtan Ahmadi, Christopher W. L. Chiu, Esther C. W. Breij, Ida Hiemstra, Maria N. Jure-Kunkel
  • Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma
    Patent number: 11845805
    Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated, high-risk DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).
    Type: Grant
    Filed: December 21, 2021
    Date of Patent: December 19, 2023
    Assignee: GENMAB A/S
    Inventors: Brian Elliott, Tahamtan Ahmadi, Christopher W. L. Chiu, Esther C. W Breij, Ida Hiemstra, Maria N. Jure-Kunkel
  • BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA
    Publication number: 20230355753
    Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., relapsed and/or refractory DLBCL eligible for autologous stem cell transplant) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-DHAX/C (rituximab, dexamethasone, cytarabine, and oxaliplatin/carboplatin).
    Type: Application
    Filed: September 10, 2021
    Publication date: November 9, 2023
    Inventors: Brian ELLIOTT, Tahamtan AHMADI
  • BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING FOLLICULAR LYMPHOMA
    Publication number: 20230357440
    Abstract: Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and bendamustine.
    Type: Application
    Filed: September 10, 2021
    Publication date: November 9, 2023
    Inventors: Brian ELLIOTT, Tahamtan AHMADI, Christopher W.L. CHIU, Esther C.W. BREIJ
  • Methods of Treating High Risk Multiple Myeloma
    Publication number: 20230340145
    Abstract: Disclosed are methods of treating a subject having high-risk multiple myeloma, methods of achieving negative minimal residual disease status in a subject having multiple myeloma, and methods of predicting a likelihood of, or decreasing a risk of, relapse and/or disease progression in a subject having multiple myeloma.
    Type: Application
    Filed: February 27, 2023
    Publication date: October 26, 2023
    Inventors: Tahamtan Ahmadi, Christopher Chiu, Ming Qi, Amy Sasser, Jordan Schecter
  • BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20 FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA
    Publication number: 20230312757
    Abstract: Provided are methods of clinical treatment of chromic lymphoblastic leukemia (CLL) inhuman subjects using a bispecific-antibody which binds to CD3 and CD20.
    Type: Application
    Filed: September 10, 2021
    Publication date: October 5, 2023
    Inventors: Brian ELLIOTT, Jenny J. CHEN, Tahamtan AHMADI, Christopher W.L. CHIU, Esther C.W. BRElJ, Ida HIEMSTRA, Maria N. JURE-KUNKEL
  • BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA
    Publication number: 20230312759
    Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., relapsed and/or refractory DLBCL ineligible for autologous stem cell transplant) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of car regimen of gemcitabine and oxaliplatin (GemOx).
    Type: Application
    Filed: September 10, 2021
    Publication date: October 5, 2023
    Inventors: Brian ELLIOTT, Tahamtan AHMADI, Patricia GARRIDO CASTRO
  • BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING FOLLICULAR LYMPHOMA
    Publication number: 20230312758
    Abstract: Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and lenalidomide.
    Type: Application
    Filed: September 10, 2021
    Publication date: October 5, 2023
    Inventors: Brian ELLIOTT, Tahamtan AHMADI, cHRISTOPHER W.L. CHIU, Esther C.W. BREIJ, Ida HIEMSTRA, Maria N. JURE-KUNKEL
  • BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20
    Publication number: 20230227570
    Abstract: The present invention relates to bispecific antibodies (bsAbs) and the use of such antibodies in the treatment of disease in subjects. Moreover, advantageous treatment regimens are provided for the treatment of B-cell Non-Hodgkin Lymphoma (B-NHL).
    Type: Application
    Filed: May 7, 2021
    Publication date: July 20, 2023
    Inventors: Tahamtan AHMADI, Manish GUPTA, Tommy R. LI, Roberto OLIVERI, Dena DEMARCO, Ida HIEMSTRA, Christopher CHIU, Brian ELLIOTT, Ada AZARYAN
  • Methods of treating high risk multiple myeloma
    Patent number: 11618787
    Abstract: Disclosed are methods of treating a subject having high-risk multiple myeloma, methods of achieving negative minimal residual disease status in a subject having multiple myeloma, and methods of predicting a likelihood of, or decreasing a risk of, relapse and/or disease progression in a subject having multiple myeloma.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: April 4, 2023
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Tahamtan Ahmadi, Christopher Chiu, Ming Qi, Amy Sasser, Jordan Schecter
  • Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma
    Patent number: 11608383
    Abstract: Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and lenalidomide.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: March 21, 2023
    Assignee: GENMAB A/S
    Inventors: Brian Elliott, Tahamtan Ahmadi, Christopher W. L. Chiu, Esther C. W. Breij, Ida Hiemstra, Maria N. Jure-Kunkel
  • Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma
    Patent number: 11548952
    Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., relapsed and/or refractory DLBCL eligible for autologous stem cell transplant) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-DHAX/C (rituximab, dexamethasone, cytarabine, and oxaliplatin/carboplatin).
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: January 10, 2023
    Assignee: GENMAB A/S
    Inventors: Brian Elliott, Tahamtan Ahmadi
  • Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma
    Patent number: 11535679
    Abstract: Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and bendamustine.
    Type: Grant
    Filed: December 21, 2021
    Date of Patent: December 27, 2022
    Assignee: GENMAB A/S
    Inventors: Brian Elliott, Tahamtan Ahmadi, Christopher W. L. Chiu, Esther C. W. Breij
  • DOSAGE REGIMENS FOR A COMBINATION OF ANTI-DR5 ANTIBODIES FOR USE IN TREATING CANCER
    Publication number: 20220315661
    Abstract: The present invention relates to a combination of two antibody molecules that bind to human DR5 antigen and their use in treating cancer. In particular, the present invention relates to dosage regimens for such anti-DR5 antibodies comprising administering to subject weekly dosages followed by biweekly dosages, or one or two priming dosage(s) followed by biweekly dosages.
    Type: Application
    Filed: May 11, 2020
    Publication date: October 6, 2022
    Inventors: Ulf FORSSMANN, Manish GUPTA, Jens Thing MORTENSEN, Merete ELLEKILDE-PEDERSEN, Marije Berber OVERDIJK, Tahamtan AHMADI